Drug Trial Radar · NCT05923866
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
92
Actual
Start
Sep 22, 2023
Primary completion
Sep 15, 2025
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.
Conditions
- Multiple System Atrophy (MSA)
Interventions
ONO-2808Drug
Oral administration of ONO-2808 at low, middle or high doses once daily for 24 weeks in the core part, for a total of 80 weeks including the extension part, and for up to an additional 72 weeks in the additional extension part
PlaceboDrug
Oral administration of placebo once daily for 24 weeks in the core part and for a total of 32 weeks including the extension part; Transition to low-dose of ONO-2808 for remainder of the extension part until week 80 and for up to an additional 72 weeks in the additional extension part
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)Time frame: From screening up to follow-up for the core part (up to Week 28)
- Incidence of TEAEs by Highest SeverityTime frame: From screening up to follow-up for the core part (up to Week 28)
- Incidence of Study Treatment-related TEAEs by Highest SeverityTime frame: From screening up to follow-up for the core part (up to Week 28)
Locations
35 sites in 2 countries. Site status is shown where the registry gives one.
The Parkinson's Movement and Disorder Institute
Fountain Valley, California
University of Southern California
Los Angeles, California
David Geffen School of Medicine at UCLA
Los Angeles, California
Stanford University School of Medicine
Palo Alto, California
CenExel Rocky Mountain Clinical Research
Englewood, Colorado
Yale School of Medicine - Yale Church Street Research Unit (CRSU)
New Haven, Connecticut
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
Norman Fixel Institute for Neurological Diseases - University of Florida
Gainesville, Florida
Mayo Clinic in Florida
Jacksonville, Florida
University of Miami Miller School of Medicine
Miami, Florida
Emory University School of Medicine
Atlanta, Georgia
University of Kansas Medical Center Research Institute
Kansas City, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
University of Michigan School of Medicine
Ann Arbor, Michigan
Quest Research Institute
Farmington Hills, Michigan
Mayo Clinic - Rochester
Rochester, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
NYU Langone Health - NYU Dysautonomia Center
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University
New York, New York
University of Cincinnati College of Medicine
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Ohio State University
Columbus, Ohio
Penn State University - Milton S. Hershey Medical Center
Hershey, Pennsylvania
The University of Pennsylvania - Pennsylvania Hospital
Philadelphia, Pennsylvania
UT Southwestern Medical Center
Dallas, Texas
Virginia Commonwealth University Medical Center
Richmond, Virginia
Evergreen Health
Kirkland, Washington
Swedish Neuroscience Institute, Movement Disorders Clinic
Seattle, Washington
Fujita Health University Hospital
Toyoake, Aichi-ken, Japan
National Hospital Organization Utano National Hospital
Kyoto, Kyoto, Japan
National Hospital Organization Sendai Nishitaga Hospital
Sendai, Miyagi, Japan
National Hospital Organization Osaka Toneyama Medical Center
Toyonaka, Osaka, Japan
Tokyo Metropolitan Neurological Hospital
Fuchū, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.